On November 29, 2023, AbbVie announced the top-line results from the single-arm Phase II LUMINOSITY trial of ABBV-399 for treating HGFR-overexpressing, EGFR wild-type, advanced/metastatic nonsquamous NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.